The Company is pleased to announce the first enrollment in its clinical evaluation to assess fit, comfort, patient placement and safety of the FemPulse therapy, as well as the potential for improvement in symptoms associated with OAB. The subject, a 69 year old female, was afflicted with urgency and urinary urge incontinence.
